Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia [11]

Leukemia

Volumn 19, Issue 2, 2005, Pages 310-312

  Gustafsson, B ^a   Angelini, S ^b   Sander, B ^a   Christensson, B ^a   Hemminki, K ^b,c   Kumar, R ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMINE; GLYCINE; ISOLEUCINE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SERINE; VALINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; APOPTOSIS; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CELL STIMULATION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COLORECTAL CANCER; CYTOGENETICS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LETTER; LEUKEMIA CELL; LEUKEMIA RELAPSE; LUNG CANCER; MALE; MELANOMA; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE N RAS; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; THYROID CANCER;

EID: 13544251719     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403589     Document Type: Letter

References (10)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-4679.
3. Perentesis JP, Bhatia S, Boyle E,Shao Y, Shu XO, Steinbuch M et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 685-692.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
5. Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G et al. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia 2003; 17: 2238-2240.
6. Smith ML, Snaddon J, Neat M, Cambal-Parrales M, Arch R, Lister TA et al. Mutation of BRAF is uncommon in AML FAB type M1 and M2. Leukemia 2003; 17: 274-275.
7. Lee JW, Soung YH, Park WS, Kim SY, Nam SW, Min WS et al. BRAF mutations in acute leukemias. Leukemia 2004; 18: 170-172.
8. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9: 3362-3368.
9. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
10. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002; 62: 188-199.